Raynaud phenomenon

Last updated 28 Mar 2026 · Inflammatory Arthritis

Introduction

Raynaud phenomenon is an episodic vasospastic disorder causing colour changes in the digits (fingers, toes, ears, nose) triggered by cold exposure or emotional stress. It is characterised by triphasic colour changes: white (pallor due to vasospasm), blue (cyanosis due to deoxygenation), and red (hyperaemia during rewarming). The condition affects 3–5% of the general population in Australia, with higher prevalence in females and in colder climates.

Raynaud phenomenon is classified as primary (idiopathic, no underlying systemic disease) or secondary (associated with connective tissue disease, autoimmune disease, or other systemic conditions). Approximately 90% of Raynaud phenomenon is primary, which generally has benign prognosis. Secondary Raynaud phenomenon requires investigation and management of the underlying condition.

Pathophysiology

Mechanism of Vasospasm

Raynaud phenomenon results from exaggerated vascular response to cold or stress. The exact mechanism involves: (1) Increased sympathetic nervous system activity in response to cold, leading to excessive vasoconstriction of digital arteries. (2) Abnormal endothelial function with reduced nitric oxide (vasodilator) and increased endothelin (vasoconstrictor). (3) Increased peripheral vascular resistance and reduced blood flow to the digits. (4) Abnormal platelet aggregation in some cases.

Primary vs. Secondary Raynaud Phenomenon

Primary Raynaud (90% of cases): Idiopathic, no associated systemic disease. Mild symptoms, no digital ulceration. Generally benign with excellent prognosis. Secondary Raynaud (10% of cases): Associated with underlying autoimmune or connective tissue disease (systemic sclerosis, systemic lupus erythematosus, rheumatoid arthritis, Sjögren syndrome, mixed connective tissue disease). More severe symptoms, risk of digital ulceration and tissue necrosis.

Clinical Presentation

Typical Episode

Triggers: Cold exposure or emotional stress. Episodes typically last 15–20 minutes but can extend for hours in severe cases. Symptoms: Numbness, tingling, pain, or throbbing sensation in affected digits during rewarming phase.

Colour Changes

White phase (pallor): Due to initial intense vasoconstriction. Digits appear pale or white. Blue phase (cyanosis): As deoxygenation of static blood in capillaries occurs. Digits appear cyanotic/purple. Red phase (hyperaemia): Upon rewarming and return of blood flow, reactive hyperaemia causes red discolouration with throbbing pain.

Red Flags for Secondary Raynaud

Asymmetrical attacks. Digital ulceration or gangrene. Severe pain during attacks. Age at onset >30 years. Abnormal nailfold capillaroscopy. Positive autoantibodies (ANA, anti-centromere, anti-Scl-70). Associated systemic symptoms (weight loss, joint pain, rash, dry eyes/mouth, dyspnoea).

Investigations

Essential
Clinical History and Examination
Detailed history of attacks (triggers, duration, colour changes, associated symptoms). Examination of digits for ulceration, scarring, or tissue loss. Digital pulses assessment.
Available
Autoantibodies (ANA, specific antibodies)
Useful if secondary Raynaud suspected (age >30, severe symptoms, digital ulceration, systemic symptoms). ANA positive in 25–30% of primary Raynaud; more common in secondary. Anti-Scl-70, anti-centromere, anti-Ro/SSA helpful if specific connective tissue disease suspected.
Available
Nailfold Capillaroscopy
Shows capillary abnormalities in secondary Raynaud (abnormal dilated capillaries, dropout). Useful in distinguishing primary from secondary Raynaud and assessing risk of systemic sclerosis.
If Abnormal Features
Rheumatology Review
If secondary Raynaud suspected (positive antibodies, abnormal capillaroscopy, severe symptoms), refer for specialist evaluation and management of underlying connective tissue disease.

Severity Grading

MILD

Infrequent Episodes

Attacks triggered only by significant cold exposure or stress. Episodes <15 minutes. No pain. No digital ulceration. Minimal functional impact.

Primary care; conservative management (cold avoidance, lifestyle measures)

MODERATE

Frequent Episodes with Functional Impact

Frequent attacks (>2 per week) triggered by mild cold exposure or stress. Episodes 15–60 minutes. Mild pain or significant paresthesias. Some functional limitation.

Primary care with conservative management; consider pharmacotherapy if significant functional impact

SEVERE

Digital Tissue Damage

Frequent, prolonged attacks. Digital ulceration, scarring, or tissue loss. Severe pain during episodes. Significant functional limitation. Risk of gangrene. Possible secondary Raynaud.

Rheumatology referral; pharmacotherapy (calcium channel blockers); consideration of specialist procedures if refractory

Directed Therapy

First-Line: Conservative Management

Cold avoidance: Wear warm gloves/mittens when exposed to cold. Avoid immersion in cold water. Use insulated water bottles for holding cold drinks. Limit outdoor exposure in winter. Use thermal socks and insulated footwear.

Stress management: Identify stress triggers for attacks. Practice stress-reduction techniques (relaxation, meditation, biofeedback).

Pharmacotherapy (Second-Line)

💊

Nifedipine (Extended-Release)

Adalat® XL · Calcium Channel Blocker

Adult Dose30 mg once daily (can increase to 60 mg daily)

RouteOral

Duration6–12 weeks to assess effect

NotesFirst-line pharmacotherapy. Reduces attack frequency and severity by 20–30% in approximately 50–70% of patients. Adverse effects: headache, flushing, ankle oedema, dizziness.

PBS Status✓ PBS General Benefit

💊

Amlodipine

Norvasc® · Calcium Channel Blocker

Adult Dose5–10 mg once daily

RouteOral

Duration6–12 weeks to assess effect

NotesLonger duration of action (24 hours), potentially more stable effect than nifedipine. Similar efficacy. Adverse effects: headache, ankle oedema (less flushing than nifedipine).

PBS Status✓ PBS General Benefit

Alternative Pharmacotherapy

If calcium channel blockers ineffective or not tolerated: (1) Alpha-blockers (prazosin 0.5–2 mg daily) — modest efficacy. (2) Nitrates (topical or oral) — modest effect, side effects limit use. (3) Phosphodiesterase-5 inhibitors (sildenafil 50 mg daily) — emerging evidence in secondary Raynaud with digital ulceration; specialist use.

Avoid: Beta-blockers (may worsen vasospasm). Ergot alkaloids. Amphetamines.

Acute Management

During an Acute Attack

Immediate measures: (1) Move to warm environment or remove from cold stimulus. (2) Immerse hands/feet in warm (not hot) water to promote vasodilatation. (3) Avoid rapid rewarming (risk of tissue damage). (4) Perform gentle hand exercises to promote blood flow. (5) Provide reassurance that attack will resolve spontaneously.

Initial Presentation Assessment

History: Age at onset, frequency and duration of attacks, triggers, colour changes, associated symptoms (joint pain, rash, dry eyes/mouth, dyspnoea). Examination: Inspect digits for ulceration, scarring, tissue loss. Check digital pulses. General examination for signs of systemic disease.

Risk stratification: Mild primary Raynaud (80%) — cold avoidance, monitoring. Moderate Raynaud with functional impact (15%) — consider pharmacotherapy. Severe Raynaud with digital ulceration or systemic features (5%) — specialist referral for evaluation of secondary Raynaud.

Monitoring and Follow-Up

Primary Raynaud Phenomenon

Initial assessment: Nailfold capillaroscopy normal, autoantibodies negative, no systemic features. Follow-up: Annual review to screen for development of secondary features (new systemic symptoms, autoantibody seroconversion, capillary changes). Reassure about benign prognosis and very low risk of tissue damage.

If Pharmacotherapy Initiated

Timing of response: Allow 6–12 weeks for pharmacotherapy to show benefit. Review at 4–6 weeks to assess tolerability of side effects. In winter months, continue pharmacotherapy; consider reducing dose or stopping in summer if symptoms resolve seasonally.

Secondary Raynaud Phenomenon

Specialist rheumatology referral indicated if: Age >30 at onset, severe symptoms, digital ulceration, positive autoantibodies, abnormal nailfold capillaroscopy, systemic features. Management directed toward underlying connective tissue disease.

Special Populations

🤰 Pregnancy

Conservative managementFirst-line is cold avoidance and lifestyle measures. Pharmacotherapy if severe and affecting function, particularly if secondary Raynaud with risk of ulceration.

Calcium channel blockers in pregnancyNifedipine is safe in pregnancy (pregnancy category A) if pharmacotherapy needed. Amlodipine has limited pregnancy data; avoid if possible.

👴 Older Adults

Medication interactionsReview for drug interactions if on multiple medications. Dose adjustments may be needed in renal impairment. Monitor blood pressure closely if on calcium channel blockers.

Aboriginal and Torres Strait Islander Health Considerations

Raynaud phenomenon prevalence in Aboriginal and Torres Strait Islander populations is not well-studied, but likely similar to other populations. However, access to diagnostics (autoantibody testing, capillaroscopy) and specialist rheumatology services may be limited in remote areas, affecting timely diagnosis of secondary Raynaud.

Access to Diagnostic Services

Autoantibody testing and capillaroscopy may not be available in remote communities. Arrange pathology via centralised services. Telehealth rheumatology consultation if secondary Raynaud suspected. Patient transport support if specialist assessment needed.

Medication Access

Calcium channel blockers should be available through PBS. Ensure affordable access and clear dispensing information. Simplify dosing (once-daily formulation preferred).

Cold Avoidance Education

Advice tailored to local environment and lifestyle. Provide written guidance with local context. Discuss specific protective measures (appropriate clothing, insulated items).

Follow-Up Attendance

Geographic distance and competing health priorities may affect follow-up. Combine Raynaud assessment with routine health visits. Use telehealth for monitoring if capacity available.

Stewardship and Key Points

Key Messages

Primary Raynaud is benign: 90% of cases have no underlying systemic disease. Prognosis is excellent with very low risk of tissue damage. Reassure patients of benign natural history.
Conservative management is first-line: Cold avoidance, stress reduction, and protective clothing are the foundation of treatment. Effective in 80% of patients with mild disease.
Secondary Raynaud requires investigation: If clinical features suggest secondary disease (age >30 at onset, severe symptoms, digital ulceration, systemic features), investigate for underlying connective tissue disease. Refer to rheumatology.
Calcium channel blockers are first-line pharmacotherapy: Nifedipine or amlodipine if pharmacotherapy needed. Modest efficacy (20–30% reduction in attack frequency).
Avoid vasoconstrictive agents: Beta-blockers, ergot alkaloids, and amphetamines can worsen Raynaud and should be avoided.

Red Flags Warranting Specialist Referral

Refer to rheumatology if: Age >30 at onset. Digital ulceration, scarring, or tissue loss. Positive autoantibodies (ANA, anti-Scl-70, anti-centromere). Abnormal nailfold capillaroscopy. Systemic symptoms. Unilateral or asymmetrical attacks (suggests alternative diagnosis).

References

01
Wigley FM. Raynaud's Phenomenon. N Engl J Med. 2002;347(13):1001-1008.
02
De Angelis R, Pivonello C, Vigorito C, et al. An up-date on the pathophysiology of peripheral vascular disease in Raynaud's phenomenon. Int J Mol Sci. 2022;23(4):2067.
03
Garcier JM, Chau Y, Diallo B, et al. Primary Raynaud phenomenon. Diagnosis and management. Vascular. 2005;13(1):29-37.
04
Australian College of Rheumatologists. Guidelines for the diagnosis and management of Raynaud phenomenon. 2023 Update.